8.49
price down icon5.35%   -0.48
after-market Handel nachbörslich: 8.52 0.03 +0.35%
loading
Schlusskurs vom Vortag:
$8.97
Offen:
$8.72
24-Stunden-Volumen:
458.26K
Relative Volume:
1.49
Marktkapitalisierung:
$592.37M
Einnahmen:
$36.90M
Nettoeinkommen (Verlust:
$-166.28M
KGV:
-2.5805
EPS:
-3.29
Netto-Cashflow:
$-203.53M
1W Leistung:
-7.72%
1M Leistung:
-22.61%
6M Leistung:
-62.48%
1J Leistung:
-65.90%
1-Tages-Spanne:
Value
$8.20
$8.90
1-Wochen-Bereich:
Value
$8.20
$9.69
52-Wochen-Spanne:
Value
$8.20
$28.67

Bicycle Therapeutics Plc Adr Stock (BCYC) Company Profile

Name
Firmenname
Bicycle Therapeutics Plc Adr
Name
Telefon
011441223261503
Name
Adresse
BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE
Name
Mitarbeiter
305
Name
Twitter
@Bicycle_tx
Name
Nächster Verdiensttermin
2024-10-31
Name
Neueste SEC-Einreichungen
Name
BCYC's Discussions on Twitter

Vergleichen Sie BCYC mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
BCYC
Bicycle Therapeutics Plc Adr
8.49 592.37M 36.90M -166.28M -203.53M -3.29
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Bicycle Therapeutics Plc Adr Stock (BCYC) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-11-08 Eingeleitet Stephens Equal-Weight
2024-09-06 Eingeleitet RBC Capital Mkts Outperform
2024-08-07 Herabstufung B. Riley Securities Buy → Neutral
2023-09-11 Hochstufung B. Riley Securities Neutral → Buy
2022-08-31 Eingeleitet Cowen Outperform
2022-07-28 Eingeleitet Barclays Overweight
2022-07-06 Fortgesetzt Canaccord Genuity Buy
2022-04-13 Herabstufung B. Riley Securities Buy → Neutral
2022-04-07 Fortgesetzt Cantor Fitzgerald Overweight
2022-02-14 Eingeleitet Morgan Stanley Equal-Weight
2021-12-17 Eingeleitet SVB Leerink Outperform
2021-12-09 Eingeleitet Needham Buy
2021-09-30 Eingeleitet B. Riley Securities Buy
2021-04-20 Eingeleitet JMP Securities Mkt Outperform
2020-10-12 Eingeleitet Cantor Fitzgerald Overweight
2020-06-12 Eingeleitet Oppenheimer Outperform
2020-04-17 Eingeleitet H.C. Wainwright Buy
2019-11-14 Eingeleitet ROTH Capital Buy
2019-09-11 Hochstufung Goldman Neutral → Buy
2019-06-17 Eingeleitet Canaccord Genuity Buy
2019-06-17 Eingeleitet Goldman Neutral
2019-06-17 Eingeleitet Jefferies Buy
2019-06-17 Eingeleitet Piper Jaffray Overweight
Alle ansehen

Bicycle Therapeutics Plc Adr Aktie (BCYC) Neueste Nachrichten

pulisher
Mar 27, 2025

Bicycle Therapeutics reshuffles leadership, aims for oncology advances By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Bicycle Therapeutics reshuffles leadership, aims for oncology advances - Investing.com India

Mar 27, 2025
pulisher
Mar 24, 2025

Bicycle Therapeutics stock hits 52-week low at $8.98 By Investing.com - Investing.com South Africa

Mar 24, 2025
pulisher
Mar 12, 2025

Bicycle Therapeutics’ SWOT analysis: innovative platform drives stock potential - Investing.com India

Mar 12, 2025
pulisher
Mar 03, 2025

Advanced Urothelial Carcinoma Clinical Trial Pipeline Analysis Demonstrates 20+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - GlobeNewswire Inc.

Mar 03, 2025
pulisher
Feb 25, 2025

Jefferies cuts Bicycle Therapeutics price target to $42 from $53 By Investing.com - Investing.com South Africa

Feb 25, 2025
pulisher
Feb 25, 2025

Bicycle Therapeutics stock holds $33 target, Buy rating at Rodman By Investing.com - Investing.com South Africa

Feb 25, 2025
pulisher
Feb 25, 2025

Mizuho maintains Harmony Biosciences $42 target, Outperform rating - Investing.com India

Feb 25, 2025
pulisher
Feb 25, 2025

Mizuho maintains Harmony Biosciences $42 target, Outperform rating By Investing.com - Investing.com South Africa

Feb 25, 2025
pulisher
Jan 15, 2025

Bicycle Therapeutics' SWOT analysis: platform potential drives stock outlook - Investing.com India

Jan 15, 2025
pulisher
Jan 13, 2025

Bicycle Therapeutics reports promising cancer drug trial results - Investing.com India

Jan 13, 2025
pulisher
Jan 07, 2025

Bicycle therapeutics CDO Santiago Arroyo sells shares worth $69,646 - Investing.com India

Jan 07, 2025
pulisher
Jan 06, 2025

Bicycle Therapeutics CFO Alethia Young sells shares totaling $19,655 - Investing.com

Jan 06, 2025
pulisher
Jan 06, 2025

Bicycle Therapeutics exec sells $30k in shares - Investing.com

Jan 06, 2025
pulisher
Jan 06, 2025

Bicycle Therapeutics CAO Travis Thompson sells $67,292 in shares By Investing.com - Investing.com South Africa

Jan 06, 2025
pulisher
Jan 06, 2025

Bicycle Therapeutics CTO sells shares worth $60,119 By Investing.com - Investing.com South Africa

Jan 06, 2025
pulisher
Jan 06, 2025

Bicycle Therapeutics CAO Travis Thompson sells $67,292 in shares - Investing.com

Jan 06, 2025
pulisher
Jan 06, 2025

Bicycle Therapeutics CEO Lee sells shares worth $172,952 By Investing.com - Investing.com South Africa

Jan 06, 2025
pulisher
Jan 06, 2025

Bicycle Therapeutics CEO Lee sells shares worth $172,952 - Investing.com India

Jan 06, 2025
pulisher
Dec 19, 2024

Bicycle Therapeutics' SWOT analysis: stock outlook amid clinical trials and cash strength - Investing.com India

Dec 19, 2024
pulisher
Dec 14, 2024

Bicycle Therapeutics' SWOT analysis: stock's potential rides on clinical data By Investing.com - Investing.com South Africa

Dec 14, 2024
pulisher
Dec 14, 2024

Bicycle Therapeutics' SWOT analysis: stock's potential rides on clinical data - Investing.com

Dec 14, 2024
pulisher
Dec 09, 2024

FDA Accepts GSK's Filing for Expanded Use of Nucala in COPD - Yahoo Finance

Dec 09, 2024
pulisher
Nov 27, 2024

ALEC Stock Tanks as Alzheimer's Drug Fails in Mid-Stage Study - Yahoo Finance

Nov 27, 2024
pulisher
Nov 25, 2024

Pharmacovigilance and Drug Safety Software Market Size to Reach USD 371.88 Million by 2032, Growing at a 6.76% CAGR – SNS Insider - Yahoo Finance

Nov 25, 2024
pulisher
Nov 21, 2024

SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study - Yahoo Finance

Nov 21, 2024
pulisher
Nov 19, 2024

ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap - Yahoo Finance

Nov 19, 2024
pulisher
Nov 15, 2024

Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer Therapy - Yahoo Finance

Nov 15, 2024
pulisher
Nov 13, 2024

Bicycle Therapeutics' SWOT analysis: innovative platform fuels stock's potential - Investing.com India

Nov 13, 2024
pulisher
Nov 13, 2024

Bicycle Therapeutics' chief accounting officer sells shares worth $157,113 - Investing.com

Nov 13, 2024
pulisher
Nov 02, 2024

Bicycle Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Nov 02, 2024
pulisher
Oct 31, 2024

Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results - Yahoo Finance

Oct 31, 2024
pulisher
Oct 28, 2024

Bicycle Therapeutics' SWOT analysis: stock's potential rides on innovative platform - Investing.com India

Oct 28, 2024
pulisher
Oct 24, 2024

Bicycle Therapeutics retains stock target and Buy rating on promising data - Investing.com

Oct 24, 2024
pulisher
Oct 23, 2024

Bicycle Therapeutics spotlights cancer treatment targets - Investing.com

Oct 23, 2024
pulisher
Oct 21, 2024

Novartis Gets CHMP Recommendation for Kisqali in Broader Population - Yahoo Finance

Oct 21, 2024
pulisher
Oct 19, 2024

Bicycle Therapeutics (BCYC) Soars 5.7%: Is Further Upside Left in the Stock? - MSN

Oct 19, 2024
pulisher
Oct 14, 2024

A company insider recently sold 3,212 shares of Bicycle Therapeutics Plc ADR [BCYC]. Should You also Consider to Sale? – Knox Daily - Knox Daily

Oct 14, 2024
pulisher
Oct 10, 2024

BCYC’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle

Oct 10, 2024
pulisher
Oct 08, 2024

Keeping an Eye on Bicycle Therapeutics Plc ADR (BCYC) After Insider Trading Activity - Knox Daily

Oct 08, 2024
pulisher
Oct 08, 2024

Bicycle Therapeutics Plc ADR (BCYC)’s stock price range in the last year - US Post News

Oct 08, 2024
pulisher
Oct 05, 2024

Bicycle therapeutics executive sells shares worth over $21k - Investing.com India

Oct 05, 2024
pulisher
Oct 05, 2024

Bicycle therapeutics executive sells shares to cover tax obligations - Investing.com India

Oct 05, 2024
pulisher
Oct 04, 2024

Bicycle therapeutics COO sells shares worth over $21k - Investing.com India

Oct 04, 2024
pulisher
Oct 04, 2024

Bicycle therapeutics CEO sells shares worth over $71k - Investing.com

Oct 04, 2024
pulisher
Oct 04, 2024

Bicycle therapeutics CTO sells shares worth over $21k - Investing.com

Oct 04, 2024
pulisher
Oct 04, 2024

Bicycle therapeutics executive sells shares worth over $5,000 - Investing.com

Oct 04, 2024

Finanzdaten der Bicycle Therapeutics Plc Adr-Aktie (BCYC)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
Kapitalisierung:     |  Volumen (24h):